MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-16-2023
Athersys Operating Cash Flow 2011-2026 | ATHX
Annual Operating Cash Flow Athersys
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -76.2 M | -61.8 M | -35.3 M | -13.4 M | -24 M | -10.9 M | - | - | -22.8 M | -17.7 M | -14.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -10.9 M | -76.2 M | -30.7 M |
Quarterly Operating Cash Flow Athersys
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -5.97 M | - | -47 M | -36.6 M | -20.2 M | - | -56.9 M | -37.2 M | -17.1 M | - | -44.5 M | -24.8 M | -12.1 M | - | -25.2 M | -17 M | -5.52 M | - | -8.78 M | -1.29 M | -5.68 M | - | -17.9 M | -11.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.11 M | - | -14 M | -10.4 M | -5.42 M | - | -10 M | -5.85 M | -1.8 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.29 M | -56.9 M | -17.9 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-184 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
45.3 M | $ 20.52 | -2.12 % | $ 2.59 B | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 164.13 | 0.15 % | $ 8.17 B | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.49 | -3.11 % | $ 15.6 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
-446 M | $ 64.24 | -3.37 % | $ 12.3 B | USA |
 |
BioAtla
BCAB
|
-104 M | $ 0.18 | -26.92 % | $ 8.6 M | USA |
 |
BioCardia
BCDA
|
-9.97 M | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-52 M | $ 8.61 | -1.66 % | $ 1.78 B | USA |
 |
Black Diamond Therapeutics
BDTX
|
-62.3 M | $ 2.4 | -3.04 % | $ 132 M | USA |
 |
Beam Therapeutics
BEAM
|
-345 M | $ 28.29 | -0.6 % | $ 2.8 B | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-831 M | $ 11.47 | -0.43 % | $ 742 M | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Biogen
BIIB
|
2.2 B | $ 187.68 | -2.16 % | $ 27.5 B | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
-19 M | $ 1.38 | -0.01 % | $ 2.04 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.91 | 2.83 % | $ 908 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
828 M | $ 60.68 | -1.7 % | $ 11.6 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
14.2 B | $ 62.54 | 0.27 % | $ 127 B | USA |
 |
Benitec Biopharma
BNTC
|
-23.6 M | $ 10.85 | -0.5 % | $ 447 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 109.85 | -0.34 % | $ 27.2 B | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
-72 M | $ 1.63 | -2.69 % | $ 4.13 M | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 8.6 | 1.9 % | $ 1.39 B | Britain |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |